Monday, June 15, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 950 of 1,261

  1. US 8030333

    Benzimidazole compound crystal

    Takeda Pharmaceutical Company Limited · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  2. US 8030331

    Allosteric modulators of metabotropic glutamate receptors

    Addex Pharma, S.A. · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  3. US 8030341

    Dmt-derivative compounds and related compositions and methods of use

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  4. US 8029788

    Variants of humanized anti-carcinoma MAb CC49

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  5. US 8029826

    Chlorite in the treatment of neurodegenerative disease

    The Regents of the University of California · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  6. US 8030287

    DNA vaccine against North American spring viremia of carp virus

    The United States of America as represented by the Secretary of the Army · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  7. US 8030297

    Controlled release corticosteroid compositions and methods for the treatment of OTIC disorders

    The Regents of the University of California · Granted Oct 4, 2011 · Expires Sep 29, 2031

    granted

  8. US 8026263

    Methods for inhibiting neoproliferative changes in blood vessel walls

    The Regents of the University of California · Granted Sep 27, 2011 · Expires Sep 22, 2031

    granted

  9. US 8026234

    Polo-like kinase inhibitors

    Takeda Pharmaceutical Company Limited · Granted Sep 27, 2011 · Expires Sep 22, 2031

    granted

  10. US 8026360

    Substituted pyridazines as stearoyl-CoA desaturase inhibitors

    Xenon Pharmaceuticals Inc. · Granted Sep 27, 2011 · Expires Sep 22, 2031

    granted

  11. US 8026226

    Medical and nutritional applications of highly refined cellulose

    Regents of the University of Minnesota · Granted Sep 27, 2011 · Expires Sep 22, 2031

    granted

  12. US 8026350

    Tumor suppressor gene, p28ING5

    The United States of America as represented by theDepartment of Health and Human Services · Granted Sep 27, 2011 · Expires Sep 22, 2031

    granted

  13. US 8026347

    Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors

    LEXICON PHARMACEUTICALS, INC. · Granted Sep 27, 2011 · Expires Sep 22, 2031

    granted

  14. US 8026284

    Enterically coated cystamine, cysteamine and derivatives thereof

    The Regents of the University of California · Granted Sep 27, 2011 · Expires Sep 22, 2031

    granted

  15. US 8025891

    Porin B (PorB) as a therapeutic target for prevention and treatment of infection by Chlamydia

    The Regents of the University of California · Granted Sep 27, 2011 · Expires Sep 22, 2031

    granted

  16. US 8025887

    Avirulent, immunogenic flavivirus chimeras

    The United States of America as represtented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention · Granted Sep 27, 2011 · Expires Sep 22, 2031

    granted

  17. US 8022190

    Immuno-molecules containing viral proteins, compositions thereof and methods of using

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Sep 20, 2011 · Expires Sep 15, 2031

    granted

  18. US 8022041

    Prodrug of an ICE inhibitor

    Vertex Pharmaceuticals Incorporated · Granted Sep 20, 2011 · Expires Sep 15, 2031

    granted

  19. US 8022094

    Carvedilol phosphate

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Granted Sep 20, 2011 · Expires Sep 15, 2031

    granted

  20. US 8022057

    MAPK/ERK kinase inhibitors

    Takeda Pharmaceutical Company Limited · Granted Sep 20, 2011 · Expires Sep 15, 2031

    granted

  21. US 8022040

    Hydroxyapatite-binding peptides for bone growth and inhibition

    The Regents of the University of California · Granted Sep 20, 2011 · Expires Sep 15, 2031

    granted

  22. US 8021874

    Very long chain polyunsaturated fatty acids, methods of production, and uses

    The Board of Regents of the University of Oklahoma · Granted Sep 20, 2011 · Expires Sep 15, 2031

    granted

  23. US 8021671

    Pro-apoptotic bacterial vaccines to enhance cellular immune responses

    The United States of America as represented by the Department of Veteran Affairs · Granted Sep 20, 2011 · Expires Sep 15, 2031

    granted

  24. US 8021646

    Compositions and methods for magnetic resonance imaging contrast agents

    Northwestern University · Granted Sep 20, 2011 · Expires Sep 15, 2031

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.